We are live on ! Find out more
AIM

AIM ImmunoTech
AIM

28 hedge funds and large institutions have $1.93M invested in AIM ImmunoTech in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% more capital invested

Capital invested by funds: $1.83M → $1.93M (+$101K)

15% less funds holding

Funds holding: 33 → 28 (-5)

17% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 6

63% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 8

Holders
28
Holders Change
-5
Holders Change %
-15.15%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
5
Reduced
6
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
+$8.87K
2
Renaissance Technologies
Renaissance Technologies
New York
+$7.79K
3
XT
XTX Topco
Cayman Islands
+$5.84K
4
Verition Fund Management
Verition Fund Management
Connecticut
+$3.73K
5
Morgan Stanley
Morgan Stanley
New York
+$3.32K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$15K
2
Bank of New York Mellon
Bank of New York Mellon
New York
-$11.1K
3
Jane Street
Jane Street
New York
-$9.35K
4
VF
Virtu Financial
New York
-$7K
5
UBS Group
UBS Group
Switzerland
-$5.35K

AIM Hedge Fund Activity: Q1 2024 in Review

28 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q1 2024, worth a combined $1.93M — up 5.5% from $1.83M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of AIM and 3 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 5 added.

The largest buyer was Two Sigma Securities, opening a new position worth an estimated $8.87K. The largest seller was Citadel Advisors, exiting entirely with an estimated $15K sold.

  • 28 institutional investors held AIM ImmunoTech (AIM) as of Q1 2024, down from 33 in Q4 2023.
  • Funds reported $1.93M of AIM ImmunoTech stock for Q1 2024, up 5.5% quarter-over-quarter.
  • 3 funds opened new AIM ImmunoTech positions in Q1 2024 and 8 closed out, a net change of -5 holders.
  • The largest AIM ImmunoTech buyer in Q1 2024 was Two Sigma Securities, an estimated $8.87K added.
  • The largest AIM ImmunoTech seller in Q1 2024 was Citadel Advisors, an estimated $15K sold.

Based on aggregated 13F filings for Q1 2024.